Get the Stockscreener App
1.89
3.08%
-0.06
After Hours:
1.90
0.01
+0.53%
Fortress Biotech Inc stock is traded at $1.89, with a volume of 192.54K.
It is down -3.08% in the last 24 hours and up +6.18% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
See More
Previous Close:
$1.95
Open:
$1.98
24h Volume:
192.54K
Relative Volume:
0.96
Market Cap:
$55.89M
Revenue:
$80.97M
Net Income/Loss:
$-78.31M
P/E Ratio:
-0.1705
EPS:
-11.0849
Net Cash Flow:
$-129.56M
1W Performance:
-3.57%
1M Performance:
+6.18%
6M Performance:
+1.61%
1Y Performance:
-12.09%
1-Day Range:
$1.88
$1.9961
1-Week Range:
$1.88
$2.03
52-Week Range:
$1.325
$2.89
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.89 | 57.96M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Fortress Biotech Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
What analysts say about Fortress Biotech Inc. stockOver 200% growth - Autocar Professional
What drives Fortress Biotech Inc. stock priceHigh-impact investment strategies - jammulinksnews.com
Will Fortress Biotech Inc. stock split in the near futureVerified Return Tips - beatles.ru
Is Fortress Biotech Inc. a good long term investmentExponentially increasing returns - jammulinksnews.com
AstraZeneca’s Anselamimab Trial Shows Mixed Results - TipRanks
Why Fortress Biotech Inc. stock attracts strong analyst attentionFree AI-Powered Stock Predictions - Newser
How Fortress Biotech Inc. stock performs during market volatilityShort Term Profit Focus - Newser
What makes Fortress Biotech Inc. stock price move sharplyMarket Ready Callouts - Newser
why fortress biotech inc. stock attracts strong analyst attentionProfessional Stock Screener - Newser
Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors - Yahoo Finance
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™ - Stock Titan
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
(FBIOP) Trading Advice - news.stocktradersdaily.com
Fortress Biotech, Inc.(NasdaqCM: FBIO) dropped from Russell 3000E Growth Index - MarketScreener
Journey Medical to Join Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Fortress Biotech shareholders approve board proposals at annual meeting - Investing.com
Journey Medical Corporation Announces Emrosi™ Data Analysis - GlobeNewswire
Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock - Nasdaq
How To Trade (FBIOP) - news.stocktradersdaily.com
Two Sigma Investments LP Invests $109,000 in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV - GlobeNewswire
Jane Street Group LLC Takes Position in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fortress Biotech, Inc. of Class Action Lawsuit and Upcoming Deadline – FBIO - ACCESS Newswire
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum - Yahoo Finance
Checkpoint Therapeutics, Inc.(NasdaqCM: CKPT) dropped from S&P TMI Index - marketscreener.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpo - GuruFocus
Fortress Biotech Announces Sale of Subsidiary Checkpoint Therapeutics - citybiz
Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics - marketscreener.com
Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit - marketscreener.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | FBIO Stock News - GuruFocus
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - GlobeNewswire
Fortress Biotech, Inc. Announces Acquisition of Checkpoint Therapeutics by Sun Pharmaceutical Industries Limited - Nasdaq
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - Benzinga
Fortress Biotech: Forging a Fortress Through Strategic Asset Realization and Portfolio Precision - AInvest
Checkpoint Therapeutics shareholders approve Sun Pharma merger By Investing.com - Investing.com India
One Fortress Biotech Insider Raised Stake By 26% In Previous Year - simplywall.st
Checkpoint Investor Sues for Info on Sale From Fortress to Sun - Bloomberg Law News
Checkpoint Pharma Sued Over Controversial $355M Merger - USA Herald
New Strong Sell Stocks for May 16th - The Globe and Mail
Q2 EPS Estimates for Fortress Biotech Raised by Roth Capital - Defense World
How the (FBIOP) price action is used to our Advantage - news.stocktradersdaily.com
Sun Pharma Q4 Consol Net PAT 21.5 Billion Rupees - marketscreener.com
Fortress Biotech Reports Q1 2025 Financial Highlights - TipRanks
Fortress Biotech First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fortress Biotech Inc (FBIO) Reports Q1 2025 Revenue of $13.1M, S - GuruFocus
Fortress Biotech: Q1 Earnings Snapshot - CT Insider
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):